Everolimus decreased IgA1 deposits in glomeruli of α1^KICD89^Tg mice. by Alexandra Cambier (22307216)

Everolimus decreased mesangial TfR1 expression in α1^KICD89^Tg mice. by Alexandra Cambier (22307216)

Linear Mixed-Effects Model analysis of bone mineral density changes in relation to urinary cadmium levels in a 3-Year Period. by Aroon La-up (14095691)

Subjects:

Cost-effectiveness acceptability curve. by Yiping An (20609789)

Subjects:

Effects of traffic loading on buried ABR pipe. by Changxi Shan (22493205)

Subjects:

Estimated coefficients from the SARIMA model of new COVID-19 cases, assuming an abrupt effect following the implementation of two ETSs and one executive order in Oregon. by Raul Cruz-Cano (3751321)

Subjects:

Estimated coefficients from the SARIMA model of new COVID-19 deaths assuming a gradual effect following the implementation of two ETSs and one executive order in Oregon. by Raul Cruz-Cano (3751321)

Subjects:

Analytical framework and statistical methods. by Na Chen (153323)

Subjects:

Theoretical frameworks of social protection. by Na Chen (153323)

Subjects:

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Probability of Cost-Effectiveness Across CET. by Yiping An (20609789)

Subjects:

Incremental cost-effectiveness scatter plot. by Yiping An (20609789)

Subjects:

Univariate and multivariate logistic regression analyses of the impact of Safe-Speed-5030 on the study population. by Hun Gi Lee (21526538)

Subjects:

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

Chlorophyll a content (A), Chlorophyll b content (B), total Chlorophyll content(C), and Chlorophyll ratio (D) of M. stenopetala leaves under the effect of different PEG concentrati... by Nadia Khater (22553166)

Subjects:

Effect of the smoking factor on lung function parameters (FVC, FEV1, PEF, FEF 25_75). by Prasanna Herath (20714794)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects: